Cargando…
High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study
ABSTRACT: Wilms’ tumor gene 1 (WT1) expression is a well-known predictor for relapse in acute myeloid leukemia. We monitored WT1 decrement along the treatment course to identify its significant role as a marker for residual disease in acute promyelocytic leukemia (APL) and tried to suggest its signi...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259829/ https://www.ncbi.nlm.nih.gov/pubmed/28114959 http://dx.doi.org/10.1186/s13045-017-0404-4 |
_version_ | 1782499282239094784 |
---|---|
author | Yoon, Jae-Ho Kim, Hee-Je Kwak, Dae-Hun Park, Sung-Soo Jeon, Young-Woo Lee, Sung-Eun Cho, Byung-Sik Eom, Ki-Seong Kim, Yoo-Jin Lee, Seok Min, Chang-Ki Cho, Seok-Goo Kim, Dong-Wook Lee, Jong Wook Min, Woo-Sung |
author_facet | Yoon, Jae-Ho Kim, Hee-Je Kwak, Dae-Hun Park, Sung-Soo Jeon, Young-Woo Lee, Sung-Eun Cho, Byung-Sik Eom, Ki-Seong Kim, Yoo-Jin Lee, Seok Min, Chang-Ki Cho, Seok-Goo Kim, Dong-Wook Lee, Jong Wook Min, Woo-Sung |
author_sort | Yoon, Jae-Ho |
collection | PubMed |
description | ABSTRACT: Wilms’ tumor gene 1 (WT1) expression is a well-known predictor for relapse in acute myeloid leukemia. We monitored WT1 decrement along the treatment course to identify its significant role as a marker for residual disease in acute promyelocytic leukemia (APL) and tried to suggest its significance for relapse prediction. In this single center retrospective study, we serially measured PML-RARa and WT1 expression from 117 APL patients at diagnosis, at post-induction and post-consolidation chemotherapies, and at every 3 months after starting maintenance therapy. All 117 patients were in molecular remission after treatment of at least 2 consolidation chemotherapies. We used WT1 ProfileQuant™ kit (Ipsogen) for WT1 monitoring. High WT1 expression (>120 copies/10(4) ABL1) after consolidation and at early period (3 months) after maintenance therapy significantly predicted subsequent relapse. All paired PML-RARa RQ-PCR were not detected except for one sample with early relapse. Patients with high WT1 expression at 3 months after maintenance therapy (n = 40) showed a significantly higher relapse rate (30.5 vs. 6.9%, P < 0.001) and inferior disease free survival (62.8 vs. 91.4%, P < 0.001). Multivariate analysis revealed that high peak leukocyte counts at diagnosis (HR = 6.4, P < 0.001) and high WT1 expression at 3 months after maintenance therapy (HR = 7.1, P < 0.001) were significant factors for prediction of relapse. Our data showed high post-remission WT1 expression was a reliable marker for prediction of subsequent molecular relapse in APL. In this high-risk group, early intervention with ATRA ± ATO, anti-CD33 antibody therapy, and WT1-specific therapy may be used for relapse prevention. TRIAL REGISTRATION: Clinical Research Information Service (CRIS), KCT0002079 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-017-0404-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5259829 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-52598292017-01-26 High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study Yoon, Jae-Ho Kim, Hee-Je Kwak, Dae-Hun Park, Sung-Soo Jeon, Young-Woo Lee, Sung-Eun Cho, Byung-Sik Eom, Ki-Seong Kim, Yoo-Jin Lee, Seok Min, Chang-Ki Cho, Seok-Goo Kim, Dong-Wook Lee, Jong Wook Min, Woo-Sung J Hematol Oncol Letter to the Editor ABSTRACT: Wilms’ tumor gene 1 (WT1) expression is a well-known predictor for relapse in acute myeloid leukemia. We monitored WT1 decrement along the treatment course to identify its significant role as a marker for residual disease in acute promyelocytic leukemia (APL) and tried to suggest its significance for relapse prediction. In this single center retrospective study, we serially measured PML-RARa and WT1 expression from 117 APL patients at diagnosis, at post-induction and post-consolidation chemotherapies, and at every 3 months after starting maintenance therapy. All 117 patients were in molecular remission after treatment of at least 2 consolidation chemotherapies. We used WT1 ProfileQuant™ kit (Ipsogen) for WT1 monitoring. High WT1 expression (>120 copies/10(4) ABL1) after consolidation and at early period (3 months) after maintenance therapy significantly predicted subsequent relapse. All paired PML-RARa RQ-PCR were not detected except for one sample with early relapse. Patients with high WT1 expression at 3 months after maintenance therapy (n = 40) showed a significantly higher relapse rate (30.5 vs. 6.9%, P < 0.001) and inferior disease free survival (62.8 vs. 91.4%, P < 0.001). Multivariate analysis revealed that high peak leukocyte counts at diagnosis (HR = 6.4, P < 0.001) and high WT1 expression at 3 months after maintenance therapy (HR = 7.1, P < 0.001) were significant factors for prediction of relapse. Our data showed high post-remission WT1 expression was a reliable marker for prediction of subsequent molecular relapse in APL. In this high-risk group, early intervention with ATRA ± ATO, anti-CD33 antibody therapy, and WT1-specific therapy may be used for relapse prevention. TRIAL REGISTRATION: Clinical Research Information Service (CRIS), KCT0002079 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-017-0404-4) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-23 /pmc/articles/PMC5259829/ /pubmed/28114959 http://dx.doi.org/10.1186/s13045-017-0404-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Letter to the Editor Yoon, Jae-Ho Kim, Hee-Je Kwak, Dae-Hun Park, Sung-Soo Jeon, Young-Woo Lee, Sung-Eun Cho, Byung-Sik Eom, Ki-Seong Kim, Yoo-Jin Lee, Seok Min, Chang-Ki Cho, Seok-Goo Kim, Dong-Wook Lee, Jong Wook Min, Woo-Sung High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study |
title | High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study |
title_full | High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study |
title_fullStr | High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study |
title_full_unstemmed | High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study |
title_short | High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study |
title_sort | high wt1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative pml-rara after anthracycline-based chemotherapy: a single-center cohort study |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259829/ https://www.ncbi.nlm.nih.gov/pubmed/28114959 http://dx.doi.org/10.1186/s13045-017-0404-4 |
work_keys_str_mv | AT yoonjaeho highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy AT kimheeje highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy AT kwakdaehun highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy AT parksungsoo highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy AT jeonyoungwoo highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy AT leesungeun highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy AT chobyungsik highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy AT eomkiseong highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy AT kimyoojin highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy AT leeseok highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy AT minchangki highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy AT choseokgoo highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy AT kimdongwook highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy AT leejongwook highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy AT minwoosung highwt1expressionisanearlypredictorforrelapseinpatientswithacutepromyelocyticleukemiainfirstremissionwithnegativepmlraraafteranthracyclinebasedchemotherapyasinglecentercohortstudy |